These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26300070)

  • 1. On probabilistic certification of combined cancer therapies using strongly uncertain models.
    Alamir M
    J Theor Biol; 2015 Nov; 384():59-69. PubMed ID: 26300070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes.
    Chareyron S; Alamir M
    J Theor Biol; 2009 Jun; 258(3):444-54. PubMed ID: 18655792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.
    de Pillis LG; Gu W; Radunskaya AE
    J Theor Biol; 2006 Feb; 238(4):841-62. PubMed ID: 16153659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy.
    Kiran KL; Lakshminarayanan S
    Biosystems; 2010 Aug; 101(2):117-26. PubMed ID: 20639123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Learning-based sensitivity analysis and feedback design for drug delivery of mixed therapy of cancer in the presence of high model uncertainties.
    Alamir M
    J Theor Biol; 2023 Jul; 568():111508. PubMed ID: 37148964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological response modifiers for the therapy of cancer.
    Herberman RB
    Ann Allergy; 1985 May; 54(5):376-80. PubMed ID: 3994067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
    Engelhart M; Lebiedz D; Sager S
    Math Biosci; 2011 Jan; 229(1):123-34. PubMed ID: 21129386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited.
    Gabrilovich DI
    Lancet Oncol; 2007 Jan; 8(1):2-3. PubMed ID: 17196504
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
    Stevenson HC; Klein HG
    Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple model predictive control for optimal drug administration of mixed immunotherapy and chemotherapy of tumours.
    Sharifi N; Ozgoli S; Ramezani A
    Comput Methods Programs Biomed; 2017 Jun; 144():13-19. PubMed ID: 28494997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A look over the horizon of cancer treatment. The internist].
    ten Bokkel Huinink WW; Simonetti GP; Dubbeldam R; van Wijk A; Rodenhuis S
    TVZ; 1989 Apr; 43(8):237-40. PubMed ID: 2500735
    [No Abstract]   [Full Text] [Related]  

  • 13. The biologic basis for combined modality treatment of cancer.
    Brady LW; Markoe AM
    Cancer Clin Trials; 1979; 2(1):5-18. PubMed ID: 93031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [What is confirmed in chemo- and immunotherapy of solid tumors. Standard protocols, studies and new developments].
    Link KH; Beger HG
    Chirurg; 1992 May; 63(5):401-9. PubMed ID: 1606855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sweet side of tumor immunotherapy.
    Freire T; Osinaga E
    Immunotherapy; 2012 Jul; 4(7):719-34. PubMed ID: 22853758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing adoptive immunotherapy of cancer.
    Westwood JA; Berry LJ; Wang LX; Duong CP; Pegram HJ; Darcy PK; Kershaw MH
    Expert Opin Biol Ther; 2010 Apr; 10(4):531-45. PubMed ID: 20132063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined chemoimmunotherapy of solid tumours: improving vaccines?
    Nowak AK; Lake RA; Robinson BW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):975-90. PubMed ID: 17005292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Past and current problems in tumor research].
    von Wasielewski E; Sedlacek HH
    Dtsch Med Wochenschr; 1986 Apr; 111(16):630-7. PubMed ID: 3956405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.